Real-Time Single Molecule Imaging Reveals Pathway-Selective Action of Aducanumab on Amyloid-β Aggregation
- 5 October 2026
- journal article
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 26 (42) , 14560-14568
Abstract
Aducanumab is an anti-amyloid-β (Aβ) antibody that binds aggregated Aβ species and has been reported to inhibit secondary nucleation on fibril surfaces. However, how antibody binding influences aggregate dynamics at the molecular level remains incompletely understood. Here, we used high-speed atomic force microscopy (HS-AFM) to directly visualize the interactions between aducanumab and Aβ42 aggregates in real time at single-molecule resolution. Aducanumab extensively decorated oligomers, protofibrils, and fibrils, with fibril binding depending on local surface structure. Consistent with its reported inhibition of secondary nucleation, bulk thioflavin T assays showed slowed aggregation. Nevertheless, in the continued presence of the antibody, protofibril formation proceeded─a pathway distinct from secondary nucleation. These observations reveal a pathway-selective mode of action: extensive surface binding and the suppression of secondary nucleation do not extend to protofibril formation, which proceeds in the continued presence of the antibody.Keywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
- Japan Society for the Promotion of Science (JP19K07965)
- Japan Society for the Promotion of Science (JP22K07514)
- Kanazawa University
This publication has 50 references indexed in Scilit:
- In vitro, cellular and in vivo studies of amyloid oligomers structure and toxicity: Challenges and advancesProtein Science, 2026
- Toxic mechanisms of amyloid oligomers and therapeutic strategiesProtein Science, 2026
- Technical advances in high-speed atomic force microscopyBiophysical Reviews, 2023
- Donanemab in Early Symptomatic Alzheimer DiseaseJAMA, 2023
- Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's DiseaseNeurotherapeutics, 2022
- Aducanumab: First ApprovalDrugs, 2021
- Emerge and Engage topline results: Phase 3 studies of aducanumab in early Alzheimer’s diseaseAlzheimer's & Dementia, 2020
- What Is the “Relevant” Amyloid β42 Concentration?ChemBioChem, 2019
- High-speed atomic force microscopy and its future prospectsBiophysical Reviews, 2017
- Transient dynamics of Aβ contribute to toxicity in Alzheimer’s diseaseCellular and Molecular Life Sciences, 2014